AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki
Paul Tunnah sat down with AstraZeneca's vice president of sustainability strategy and engagement Jim Massey to discuss how the global pharma company is embracing a green future.